Canopy Growth Corporation (CGC)
USD 2.83
(-7.21%)
USD 2.83
(-7.21%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 297.14 Million CAD | -26.25% |
| 2022 | 402.9 Million USD | -22.57% |
| 2021 | 520.32 Million CAD | -4.82% |
| 2020 | 546.64 Million CAD | 37.08% |
| 2019 | 398.77 Million CAD | 76.18% |
| 2018 | 226.34 Million CAD | 190.37% |
| 2017 | 77.94 Million CAD | 95.38% |
| 2016 | 39.89 Million CAD | 214.16% |
| 2015 | 12.69 Million CAD | 1008.44% |
| 2014 | 1.14 Million CAD | 0.0% |
| 2013 | - CAD | -100.0% |
| 2012 | 4144.00 CAD | 0.0% |
| 2011 | - CAD | -100.0% |
| 2010 | 4488.00 CAD | 717.49% |
| 2009 | 549.00 CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 48.38 Million USD | -9.03% |
| 2023 Q3 | 78.5 Million USD | -4.35% |
| 2023 FY | 297.14 Million USD | -26.25% |
| 2023 Q1 | 108.72 Million USD | 24.21% |
| 2023 Q2 | 82.07 Million USD | -24.51% |
| 2023 Q4 | 53.73 Million USD | -31.56% |
| 2022 Q3 | 101.21 Million CAD | -14.13% |
| 2022 FY | 402.9 Million USD | -22.57% |
| 2022 Q1 | 110.11 Million CAD | -1.48% |
| 2022 Q4 | 87.53 Million USD | -13.51% |
| 2022 Q2 | 117.86 Million CAD | 7.04% |
| 2021 Q1 | 136.2 Million CAD | -8.24% |
| 2021 Q2 | 131.37 Million CAD | -3.55% |
| 2021 Q3 | 140.97 Million CAD | 7.31% |
| 2021 Q4 | 111.77 Million CAD | -20.71% |
| 2021 FY | 520.32 Million CAD | -4.82% |
| 2020 Q2 | 135.26 Million CAD | 22.51% |
| 2020 Q3 | 152.52 Million CAD | 12.76% |
| 2020 Q4 | 148.43 Million CAD | -2.68% |
| 2020 Q1 | 110.41 Million CAD | 2.32% |
| 2020 FY | 546.64 Million CAD | 37.08% |
| 2019 Q2 | 76.61 Million CAD | -15.33% |
| 2019 Q1 | 90.48 Million CAD | -3.79% |
| 2019 Q4 | 107.91 Million CAD | -12.81% |
| 2019 FY | 398.77 Million CAD | 76.18% |
| 2019 Q3 | 123.76 Million CAD | 61.54% |
| 2018 FY | 226.34 Million CAD | 190.37% |
| 2018 Q1 | 25.91 Million CAD | 13.64% |
| 2018 Q2 | 23.32 Million CAD | -9.99% |
| 2018 Q3 | 83.04 Million CAD | 256.02% |
| 2018 Q4 | 94.05 Million CAD | 13.25% |
| 2017 FY | 77.94 Million CAD | 95.38% |
| 2017 Q4 | 22.8 Million CAD | 5.1% |
| 2017 Q3 | 21.7 Million CAD | 23.51% |
| 2017 Q2 | 17.56 Million CAD | 10.68% |
| 2017 Q1 | 15.87 Million CAD | 8.27% |
| 2016 FY | 39.89 Million CAD | 214.16% |
| 2016 Q4 | 14.66 Million CAD | 50.34% |
| 2016 Q2 | 8.49 Million CAD | 21.68% |
| 2016 Q1 | 6.98 Million CAD | 38.52% |
| 2016 Q3 | 9.75 Million CAD | 14.76% |
| 2015 Q4 | 5.04 Million CAD | 44.84% |
| 2015 FY | 12.69 Million CAD | 1008.44% |
| 2015 Q3 | 3.48 Million CAD | 41.15% |
| 2015 Q2 | 2.46 Million CAD | 44.2% |
| 2015 Q1 | 1.71 Million CAD | 127.78% |
| 2014 Q1 | 188.73 Thousand CAD | 0.0% |
| 2014 FY | 1.14 Million CAD | 0.0% |
| 2014 Q4 | 750.8 Thousand CAD | 17.07% |
| 2014 Q3 | 641.3 Thousand CAD | 102.87% |
| 2014 Q2 | 316.11 Thousand CAD | 67.49% |
| 2013 Q2 | 997.00 CAD | -0.1% |
| 2013 Q3 | 48.00 CAD | -95.19% |
| 2013 FY | - CAD | -100.0% |
| 2013 Q4 | - CAD | -100.0% |
| 2013 Q1 | 998.00 CAD | 3.42% |
| 2012 Q4 | 965.00 CAD | -3.69% |
| 2012 Q1 | 1002.00 CAD | 0.0% |
| 2012 Q2 | - CAD | -100.0% |
| 2012 Q3 | 1002.00 CAD | 0.0% |
| 2012 FY | 4144.00 CAD | 0.0% |
| 2011 Q4 | - CAD | -100.0% |
| 2011 Q3 | 1185.00 CAD | -4.97% |
| 2011 Q1 | 1247.00 CAD | 3.31% |
| 2011 FY | - CAD | -100.0% |
| 2011 Q2 | 1247.00 CAD | 0.0% |
| 2010 Q4 | 1207.00 CAD | -18.72% |
| 2010 Q3 | 1485.00 CAD | 0.0% |
| 2010 Q2 | - CAD | -100.0% |
| 2010 Q1 | 549.00 CAD | 0.0% |
| 2010 FY | 4488.00 CAD | 717.49% |
| 2009 FY | 549.00 CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Theratechnologies Inc. | 81.76 Million USD | -263.419% |
| Harrow Health, Inc. | 130.19 Million USD | -128.235% |
| Dynavax Technologies Corporation | 232.28 Million USD | -27.924% |
| Biofrontera Inc. | 34.07 Million USD | -772.138% |
| Cronos Group Inc. | 88.84 Million USD | -234.47% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -2233.302% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 32.884% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -4462.231% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -651.27% |
| Radius Health, Inc. | 2.88 Billion USD | 89.69% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -819.708% |
| DURECT Corporation | 8.54 Million USD | -3376.205% |
| ProPhase Labs, Inc. | 44.38 Million USD | -569.489% |
| Safety Shot Inc | 202.67 Thousand USD | -146515.681% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 70.802% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -15308.165% |
| Alvotech | 91.43 Million USD | -224.984% |
| Assertio Holdings, Inc. | 152.06 Million USD | -95.402% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 51.089% |
| Rockwell Medical, Inc. | 83.61 Million USD | -255.387% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -1133.34% |
| Procaps Group S.A. | 409.92 Million USD | 27.511% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 36.011% |
| SCYNEXIS, Inc. | 140.14 Million USD | -112.034% |
| Aytu BioPharma, Inc. | 81 Million USD | -266.838% |
| Viatris Inc. | 15.42 Billion USD | 98.074% |
| OptiNose, Inc. | 70.98 Million USD | -318.592% |
| SIGA Technologies, Inc. | 139.91 Million USD | -112.373% |
| Tilray Brands, Inc. | 788.94 Million USD | 62.336% |
| PetIQ, Inc. | 1.1 Billion USD | 73.035% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -1133.34% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 84.254% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -2325.969% |
| Alimera Sciences, Inc. | 80.75 Million USD | -267.964% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 47.572% |
| Silver Spike Investment Corp. | 11.72 Million USD | -2434.914% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 31.397% |
| Journey Medical Corporation | 79.18 Million USD | -275.274% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -5003.507% |
| Alpha Teknova, Inc. | 36.68 Million USD | -710.015% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -1606.069% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -131.673% |
| PainReform Ltd. | - USD | -Infinity% |
| Cosmos Health Inc. | 53.37 Million USD | -456.694% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -962.64% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -22722.273% |
| Embecta Corp. | 1.12 Billion USD | 73.488% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Talphera, Inc. | 651 Thousand USD | -45544.547% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 55.977% |
| Incannex Healthcare Limited | 12 Thousand USD | -2476116.667% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -27505.409% |
| Shineco, Inc. | 9.8 Million USD | -2931.528% |
| Procaps Group, S.A. | 409.92 Million USD | 27.511% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 38.961% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -487.442% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 77.08% |
| Alvotech | 91.43 Million USD | -224.984% |
| Hempacco Co., Inc. | 4.04 Million USD | -7244.851% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 6.148% |
| Bright Green Corporation | 401.49 Thousand USD | -73910.625% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -155.425% |
| Kamada Ltd. | 144.75 Million USD | -105.27% |
| Indivior PLC | 1.09 Billion USD | 72.814% |
| Evoke Pharma, Inc. | 5.18 Million USD | -5635.712% |
| Flora Growth Corp. | 76.07 Million USD | -290.617% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -27505.409% |
| Evolus, Inc. | 202.08 Million USD | -47.04% |
| HUTCHMED (China) Limited | 837.99 Million USD | 64.541% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 53.888% |
| Akanda Corp. | 2.16 Million USD | -13656.428% |